Swiss National Bank Arrowhead Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 218,300 shares of ARWR stock, worth $4.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

218,300

Previous 243,300 10.28%

Holding current value

$4.53 Million

Previous $6.32 Million 33.16%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$19.36 - $29.54 $484,000 - $738,500	-25,000 Reduced 10.28%	218,300 $4.23 Million
Q1 2024 May 07, 2024	BUY	$27.21 - $39.48 $1.16 Million - $1.68 Million	42,600 Added 21.23%	243,300 $6.96 Million
Q4 2023 Feb 06, 2024	SELL	$21.2 - $31.03 $479,120 - $701,278	-22,600 Reduced 10.12%	200,700 $6.14 Million
Q3 2023 Nov 08, 2023	SELL	$26.2 - $36.08 $18,340 - $25,256	-700 Reduced 0.31%	223,300 $6 Million
Q2 2023 Aug 09, 2023	BUY	$25.16 - $41.38 $168,572 - $277,246	6,700 Added 3.08%	224,000 $7.99 Million
Q1 2023 May 10, 2023	SELL	$23.68 - $38.51 $603,840 - $982,005	-25,500 Reduced 10.5%	217,300 $5.52 Million
Q4 2022 Feb 08, 2023	BUY	$28.0 - $40.56 $128,800 - $186,576	4,600 Added 1.93%	242,800 $9.85 Million
Q3 2022 Nov 09, 2022	BUY	$29.63 - $48.31 $62,223 - $101,451	2,100 Added 0.89%	238,200 $7.87 Million
Q2 2022 Aug 09, 2022	BUY	$27.79 - $50.61 $36,127 - $65,793	1,300 Added 0.55%	236,100 $8.31 Million
Q1 2022 May 09, 2022	BUY	$39.62 - $69.97 $665,616 - $1.18 Million	16,800 Added 7.71%	234,800 $10.8 Million
Q4 2021 Feb 08, 2022	SELL	$58.09 - $82.51 $29,045 - $41,255	-500 Reduced 0.23%	218,000 $14.5 Million
Q3 2021 Nov 08, 2021	BUY	$58.38 - $84.96 $70,056 - $101,951	1,200 Added 0.55%	218,500 $13.6 Million
Q2 2021 Aug 06, 2021	SELL	$62.15 - $90.32 $354,255 - $514,823	-5,700 Reduced 2.56%	217,300 $18 Million
Q1 2021 May 07, 2021	BUY	$61.35 - $90.47 $202,455 - $298,551	3,300 Added 1.5%	223,000 $14.8 Million
Q4 2020 Feb 05, 2021	BUY	$43.82 - $85.37 $26,292 - $51,222	600 Added 0.27%	219,700 $16.9 Million
Q3 2020 Nov 09, 2020	BUY	$33.21 - $51.27 $119,556 - $184,572	3,600 Added 1.67%	219,100 $9.43 Million
Q2 2020 Aug 05, 2020	BUY	$26.12 - $43.27 $1.26 Million - $2.09 Million	48,400 Added 28.96%	215,500 $9.31 Million
Q1 2020 May 08, 2020	BUY	$20.56 - $63.12 $59,623 - $183,048	2,900 Added 1.77%	167,100 $4.81 Million
Q4 2019 Feb 06, 2020	BUY	$28.14 - $73.01 $101,304 - $262,836	3,600 Added 2.24%	164,200 $10.4 Million
Q3 2019 Nov 12, 2019	BUY	$26.26 - $34.86 $73,528 - $97,608	2,800 Added 1.77%	160,600 $4.53 Million
Q2 2019 Aug 02, 2019	BUY	$17.43 - $28.82 $233,562 - $386,188	13,400 Added 9.28%	157,800 $4.18 Million
Q1 2019 May 10, 2019	BUY	$12.05 - $20.18 $51,815 - $86,774	4,300 Added 3.07%	144,400 $2.65 Million
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $44,034 - $80,770	4,100 Added 3.01%	140,100 $1.74 Million
Q2 2018 Aug 09, 2018	BUY	$6.37 - $14.02 $866,320 - $1.91 Million	136,000 New	136,000 $1.85 Million

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.5M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Arrowhead Pharmaceuticals, Inc. Transaction History